Frequently asked questions
In 2022, the global Helicobacter Pylori Testing Market is expected to be worth USD 0.4 million.
The Helicobacter Pylori Testing Market is estimated to increase at a CAGR of 6.80% between 2023 and 2030, reaching USD 0.7 Million in 2030.
The immunoassay segment led the market in 2022
The adult category has the most market demand
The diagnostic laboratories sector is predicted to increase at the quickest CAGR
North America had the highest revenue share in the Helicobacter Pylori Testing Market in 2022, accounting for 40.1%.
The top players include Thermo Fisher Scientific Inc. , F. Hoffmann-La Roche Ltd., Gulf Coast Scientific, Biohit Oyj, Avanos Medical, Inc., Cardinal Health Inc., Meridian Bioscience, Inc
The rising prevalence of Helicobacter pylori infections fuels demand for H. pylori diagnostics. Increasing public awareness of the necessity of early detection and treatment of Helicobacter pylori, Advances in diagnostic technology and testing procedures improve the accuracy and efficiency of H. pylori testing, which are all important market drivers.
There is a scarcity of skilled professionals. The market has hurdles such as high prices associated with H. pylori testing and a lack of consistency in testing techniques and interpretation of test findings, which generates complications in the industry.
Growing need for non-invasive testing methods, increased emphasis on H. pylori point-of-care testing, and emerging markets and underserved regions all create prospects for market penetration and expansion.